Rubius Therapeutics has torn up its strategy. After reviewing human data on its lead candidates, the cell therapy biotech concluded investment in its two clinical prospects “is no longer justified,” ...

Rubius Therapeutics has pulled in another $100 million to fund the advance of its red blood cell therapies. The crossover round, which brings Rubius’ nine-month haul up to $220 million, comes as the ...

The Spanish-Norwegian influencer Rubén Doblas Gundersen will launch the new gaming show 'Rubius Checkpoint' on the new streaming platform next year. By Scott Roxborough Europe Bureau Chief Rubén ...

Rubius Therapeutics, Inc. (RUBY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Most cell therapies in development use a T cell or some other type of immune cell that’s engineered to perform a particular therapeutic task. Rubius Therapeutics makes its cell therapies from red ...

Rubius Therapeutics shares surged 84% during Monday's trading session. The biotech firm outlined encouraging data from testing of RTX-240, a potential cancer treatment. Rubius said data collected ...

Enthusiasm in the immuno-oncology therapies being developed by Rubius Therapeutics has allowed the biotech to quickly raise $220 million, a large chunk of which it will invest in a cell therapy ...

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red ...

Cell therapy is one of the big ideas in biotech. Entrepreneurs have become captivated by possibilities of engineering white blood cells so they can be re-infused into patients and fight cancer. One ...